Exelixis (EXEL)
Develops and commercializes cancer medicines around cabozantinib and a broader oncology pipeline.
$58.49
vs last close+1.27 (+2.21%)
Something off on this page? Send us feedback.
Next report
Nov 3, 26
in 42 days
EPS estimate
$0.89
Revenue estimate
$649.6M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Jul '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$0.55$0.62$0.75$0.78$0.94$0.87$0.91Pending
Estimate$0.51$0.36$0.65$0.69$0.77$0.77$0.85$0.89
Surprise+7.8%+73.1%+15.4%+13.9%+22.1%+13.7%+6.7%—
RevenueReportedEstimate
Feb '25May '25Jul '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$566.8M$555.4M$568.3M$597.8M$598.7M$610.8M$628.7MPending
Estimate$563.2M$499.6M$594.9M$590.2M$596.5M$607.5M$636.4M$649.6M
Surprise+0.6%+11.2%−4.5%+1.3%+0.4%+0.5%−1.2%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Jan 2029 | $1.14 | — | — |
| Oct 2028 | $1.10 | — | — |
| Jul 2028 | $1.07 | — | — |
| Apr 2028 | $1.04 | — | — |
| Jan 2028 | $1.02 | — | — |
| Oct 2027 | $1.06 | — | — |
| Jul 2027 | $1.01 | — | — |
| Apr 2027 | $0.95 | — | — |
| Jan 2027 | $0.85 | — | — |
| Nov 2026 | $0.89 | — | — |
| Aug 2026 | $0.85 | $0.91 | +6.7% |
| May 2026 | $0.77 | $0.87 | +13.7% |
| Feb 2026 | $0.77 | $0.94 | +22.1% |
| Nov 2025 | $0.69 | $0.78 | +13.9% |
| Jul 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| Sep 2016 | |||
| May 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Jan 2029 | $1.14 | — | — | $883.3M | — | — | — |
| Oct 2028 | $1.10 | — | — | $850.8M | — | — | — |
| Jul 2028 | $1.07 | — | — | $824.0M | — | — | — |
| Apr 2028 | $1.04 | — | — | $802.5M | — | — | — |
| Jan 2028 | $1.02 | — | — | $745.4M | — | — | — |
| Oct 2027 | $1.06 | — | — | $724.8M | — | — | — |
| Jul 2027 | $1.01 | — | — | $699.3M | — | — | — |
| Apr 2027 | $0.95 | — | — | $671.4M | — | — | — |
| Jan 2027 | $0.85 | — | — | $660.7M | — | — | — |
| Nov 3, 2026 | $0.89 | — | — | $649.6M | — | — | — |
| Aug 5, 2026 | $0.85 | $0.91 | +6.7% | $636.4M | $628.7M | −1.2% | −7.9% |
| May 5, 2026 | $0.77 | $0.87 | +13.7% | $607.5M | $610.8M | +0.5% | +9.6% |
| Feb 10, 2026 | $0.77 | $0.94 | +22.1% | $596.5M | $598.7M | +0.4% | −0.1% |
| Nov 4, 2025 | $0.69 | $0.78 | +13.9% | $590.2M | $597.8M | +1.3% | +6.5% |
| Jul 28, 2025 | |||||||
| May 13, 2025 | |||||||
| Feb 11, 2025 | |||||||
| Oct 29, 2024 | |||||||
| Aug 6, 2024 | |||||||
| Apr 30, 2024 | |||||||
| Feb 6, 2024 | |||||||
| Nov 1, 2023 | |||||||
| Aug 1, 2023 | |||||||
| May 9, 2023 | |||||||
| Feb 7, 2023 | |||||||
| Nov 1, 2022 | |||||||
| Aug 9, 2022 | |||||||
| May 10, 2022 | |||||||
| Feb 17, 2022 | |||||||
| Nov 2, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Feb 10, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 5, 2020 | |||||||
| Feb 25, 2020 | |||||||
| Oct 30, 2019 | |||||||
| Jul 31, 2019 | |||||||
| May 1, 2019 | |||||||
| Feb 12, 2019 | |||||||
| Nov 1, 2018 | |||||||
| Aug 1, 2018 | |||||||
| May 2, 2018 | |||||||
| Feb 26, 2018 | |||||||
| Nov 1, 2017 | |||||||
| Aug 2, 2017 | |||||||
| May 1, 2017 | |||||||
| Feb 27, 2017 | |||||||
| Nov 3, 2016 | |||||||
| Aug 3, 2016 | |||||||
| Sep 30, 2016 | |||||||
| May 4, 2016 | |||||||
| Nov 10, 2015 | |||||||
| Aug 11, 2015 |